http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007075297-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b1ae6b4a1af79b63ddf666a1485153ee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7f4a6eeb105d0f62cc76e6cd26fa075b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b9cc2d8f832624f015bd24bec47ef697
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_75d26c28dc2efd3ad48ea50e807cd6a3
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4436
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-305
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D453-02
filingDate 2006-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2063f22ae8780edf7b7b442f51098726
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eac8ada6084beabd4515dd3738777e74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22bd5be19550e0e6f7fdb8758b035c9a
publicationDate 2008-01-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2007075297-A3
titleOfInvention Muscarinic agonists and methods of use thereof
abstract A method of forming analogs of CDD- 0304, i.e., tetra(ethyleneglycol) (4-methoxy- 1,2,5-thiadiazol-3 -yl)[3 -(1 -methyl- 1.2,4,5-tetrahydropyrid-3 -yl)- 1,2,5-thiadiazol-4-yl]ether hydrochloride includes one or more of the following steps: a) replacing the tetrahydropyridine moiety with one of the following heterocyclic rings, including quinuclidine, [2.2.1]-exo- azabicycloheptane, [2.2.1]-endo-azabicycloheptane and terahydropyrimidine; b) varying the length of the linking group by replacing the tetra (ethylene) glycol moiety with one of: ethylene glycol, di(ethylene) glycol, penta(ethylene) glycol, or diether diol; and/or, c) replacing the 1,2,5-thiadiazole moiety with an ester isostere. Also, a method for an asymmetric analog CCD-0304 includes replacing at least one moiety with an ester isostere and at least a second moiety with an ammonium isostere. Also, such analogs compounds and their uses are disclosed.
priorityDate 2005-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-02060444-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9613167-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID22013381
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559564
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226408848
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID174
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419572113
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226509365
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7527
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559542
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419544759
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID230852881
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID417430547
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID559537
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID454241110
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226538567
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID69264546
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457465615
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID19075556
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6325
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID223
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425171162
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8200

Total number of triples: 50.